Thanks to Gramerley for supporting the Industry Focus Show. Gramerley is a communication tool that helps people

improve their writing to be mistake-free, clear, and effective.

Start writing confidently by going to Gramerly.com slash fool to get 20% off a grammarly

premium account today.

Welcome to Industry Focus, the podcast that dives into a different sector of the stock market every single day.

Today is Wednesday, September the 11th, and we're talking health care.

Todd Campbell, health care guru joining us via Skype. Todd how you doing over there?

It's good there this is a health care show because I think I need some health care

I'm battling a cold listener I apologize apologize. I'm going to do my best here

to get us through some interesting subject matter. Just bear with me a little bit.

Yes, yes. And actually Dodd, I know you're under the weather today, but I'm hoping you'll feel better because we've got lots

of good news for you to digest this week in the biotech space.

You know, often we're talking about pipeline blow-ups, bad study results, all kind of craziness in the health care

sector. So it's always nice to have a show where we've got some really good positive

data coming out of the space.

So with that, let's kick it off.

I want to start with Acadia Pharmaceuticals,

that's ticker symbol ACAD

for our listeners out there.

It's a commercial stage biotech that specializes in CNS

central nervous system disorders. Currently sports a market cap of about 5.9

billion dollars. Stock is up 156% year to date this year Todd. Pretty amazing

...